LB Pharmaceuticals (LBRX) Stock Overview
A clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LBRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
LB Pharmaceuticals Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.40 |
| 52 Week High | US$23.15 |
| 52 Week Low | US$13.36 |
| Beta | 0 |
| 1 Month Change | 20.29% |
| 3 Month Change | 35.79% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 23.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| LBRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.4% | 0.6% | -0.2% |
| 1Y | n/a | 26.8% | 17.1% |
Return vs Industry: Insufficient data to determine how LBRX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LBRX performed against the US Market.
Price Volatility
| LBRX volatility | |
|---|---|
| LBRX Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: LBRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LBRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 16 | Heather Turner | lbpharma.us |
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in pr clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
LB Pharmaceuticals Inc Fundamentals Summary
| LBRX fundamental statistics | |
|---|---|
| Market cap | US$541.40m |
| Earnings (TTM) | -US$18.80m |
| Revenue (TTM) | n/a |
Is LBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$18.80m |
| Earnings | -US$18.80m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LBRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/30 20:31 |
| End of Day Share Price | 2025/12/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LB Pharmaceuticals Inc is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marc Goodman | Leerink Partners LLC |
| Yasmeen Rahimi | Piper Sandler Companies |
| Paul Matteis | Stifel, Equities Research |